Vienna, 01.06.2026. AOP Health has received a major recognition: the pharmaceutical company won first place at the 2026 WKO Export Awards. The award honors the international success of a company founded in Vienna 30 years ago with the aim of researching and developing therapies for niche indications. At the same time, it underscores the potential of Austrian innovation. Since its founding, AOP Health has grown from a start-up into a global provider of therapies for rare diseases and intensive care. Today, the company exports highly specialized therapeutic solutions from Austria to international markets, combining scientific excellence with sustainable growth. In 2025, AOP Health provided more than 300 highly qualified jobs at its Vienna site alone and generated revenue of more than EUR 450 million.
The award comes at a challenging time for the economy. Austria’s exports remain under pressure1, yet internationally successful companies continue to be essential drivers of growth, employment and prosperity. According to the WKO, exports account for more than half of Austria’s economic output2. Against this backdrop, AOP Health exemplifies the kind of innovation that can create global impact from Austria.
30 Years of Research and Development in Vienna
Founded in Austria, AOP Health has grown continuously over the past three decades and is still privately owned and led by its founders. The company bundles all research and development activities at its headquarters in Vienna, from where it manages its international expansion — including its most recent step into the United States. Since establishing its US subsidiary in mid-2025, AOP Health has successfully marketed a self-developed intensive care product in the US. The local team works in close coordination with the Austrian headquarters.
